OakChart

Can-Fite Biopharma Ltd ADR

CANFHealthcare·Biotechnology·Israel·Nano·AMEX·Nov 11 • 12:27 PM ET

1.60-0.06 (-3.62%)
2026-11-11 18:32 CET
Market cap
5.04 USD m
Revenue, TTM
0.41 USD m
Net income, TTM
-9.61 USD m
Free cash flow, TTM
-9.56 USD m
EPS diluted, TTM
-6.30
P/E
-
Compare

Price

CANF against its 20, 50 and 200-day averages
2050200earnings
2.004.006.0028.7M57.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CANFclose 1.6020-day 1.7150-day 1.99200-day 3.111.60

87.0% under the 52-week high of 12.30 on 18 Nov 2025. 52-week low 1.50 on 4 Nov 2026. Last 15 sessions, 27.3% high to low

Profile

CANF
52-week range, 1% of the way up
1.5012.30

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Employees5
IPONov 01, 2012
Beta1.19
ATR, 14d0.10
Rel volume0.03
Inst own1.95%

Snapshot

6 groups

Valuation

Index-
Market Cap4.86M
Enterprise Value-2.13M
Income-9.61M
Sales0.41M
Book/sh2.27
Cash/sh2.32
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPONov 01, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S11.86
P/B0.71
P/C0.69
P/FCF-
EV/EBITDA-
EV/Sales-5.19
Quick Ratio3.60
Current Ratio3.60
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-6.30
EPS next Y-0.91
EPS next Q-0.80
EPS this Y65.83%
EPS next Y55.39%
EPS next 5Y52.50%
EPS past 3/5Y45.54% 45.72%
Sales past 3/5Y-20.32% -11.88%
EPS Y/Y TTM82.96%
Sales Y/Y TTM-
EPS Q/Q66.85%
Sales Q/Q-20.25%
EarningsSep 08 BMO
EPS/Sales Surpr.0.00% -

Ownership

Insider Own-
Insider Trans-
Inst Own1.95%
Inst Trans-4.93%
ROA-121.89%
ROE-212.72%
ROIC-197.98%
Gross Margin99.51%
Oper. Margin-2402.92%
Profit Margin-2358.72%
SMA20-6.63%
SMA50-19.60%
SMA200-48.49%
Trades-

Technical

Shs Outstand0.23M
Shs Float-
Short Float-
Short Ratio0.08
Short Interest0.03M
52W High12.30 -86.99%
52W Low1.50 6.66%
Volatility7.06% 5.63%
ATR (14)0.10
RSI (14)31.72
Beta1.19
Rel Volume0.03
Avg Volume370.17K
Volume6,336

Performance

Perf Week-4.14%
Perf Month-17.95%
Perf Quarter-52.94%
Perf Half Y-56.05%
Perf YTD-60.00%
Perf Year-79.77%
Perf 3Y-95.88%
Perf 5Y-99.43%
Perf 10Y-99.98%
Recom1.00
Target Price8.00
Prev Close1.66
Price1.60
Change %-3.62%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
May 13, 2026UpgradeDD. Boral CapitalHold → Buy$7+337.5%
Aug 11, 2017InitiatedMMaxim GroupBuy$7+337.5%
Oct 19, 2016ResumedRROTH CapitalBuy
Aug 29, 2016ResumedRRodman & RenshawBuy$6+275.0%
Nov 30, 2015ReiteratedHH.C. WainwrightBuy$4 → $6+275.0%
Mar 31, 2015ReiteratedHH.C. WainwrightBuy$7 → $3+87.5%
Mar 30, 2015DowngradeRROTH CapitalBuy → Neutral$20 → $2.40+50.0%
Dec 29, 2014ReiteratedRROTH CapitalBuy$28 → $20+1,150.1%
Nov 18, 2014InitiatedHH.C. WainwrightBuy$7+337.5%

Peers

Mkt cap
TickerCompanyMkt cap
CMMBChemomab Therapeutics Ltd ADR9.35M
BLRXBioline Rx Ltd ADR7.45M
CRVSCorvus Pharmaceuticals Inc981.88M
GALTGalectin Therapeutics Inc339.36M
PPBTPurple Biotech Ltd ADR2.12M
XTLBX.T.L. Biopharmaceuticals Ltd ADR7.19M
ENLVEnlivex Ltd1.82M
EDSAEdesa Biotech Inc26.11M
TLSATiziana Life Sciences Ltd83.84M
ENTXEntera Bio Ltd564.21M

News

latest 14 of 200
  • Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study (GlobeNewswire)
  • Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones (GlobeNewswire)
  • Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome (GlobeNewswire)
  • Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 (GlobeNewswire)
  • Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation (GlobeNewswire)
  • Loading…
  • Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study (GlobeNewswire)
  • Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds (GlobeNewswire) -28.27%
  • Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study (GlobeNewswire)
  • Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer (GlobeNewswire) +5.29%
  • Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates (GlobeNewswire)
  • Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome (GlobeNewswire)
  • Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology (GlobeNewswire)
  • Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-09-08-0.330-0.330-2.4970.20-1
2025S22026-03-26-5.970--3.8020.20--
2025S12025-08-280.000--8.6480.20--
2025Q12025-05-22-2.000-2.000-2.0000.00-1
2024Q42025-04-14-3.800--3.8000.20--
2024Q32024-11-29-5.400-5.400-7.0000.300.151
2024Q22024-08-29-6.600-2.200-3.8000.100.301
2024Q12024-05-30-7.000-8.100-7.0000.300.302
2023Q42024-03-28-7.900-5.300-0.180.202
2023Q32023-11-30-5.300-8.600-8.7320.200.202
2023S12023-08-310.000--0.39--
2023Q12023-06-010.000-14.200-12.8390.20-1
2022Q42023-03-30-14.800-18.278-22.1410.800.503
2022Q32022-11-25-25.550-22.000-18.4510.340.203
2022Q22022-08-25-20.686-21.000-15.9500.340.253
2022Q12022-05-260.000-28.026-17.9190.210.132

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-660.66-3,882-884.612.031.82
2020FY-240.24-184.17-255.520.760.75
2021FY-6.006-110.6-165.050.850.84
2022FY-60.060-69.908-74.5270.811.21
2023FY-60.060-26.900-35.7280.740.69
2024FY-10.589-24.376-21.8230.670.00
2025FY-5.970-0.520-5.9700.410.20
2026FY--2.040--0.40
2027FY--0.910--0.40
2028FY--0.640--15.26
2029FY-0.070--58.42
2030FY-0.380--94.87

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-09-281000.200.200.20
2026S2E2026-09-28101-0.80-0.80-0.80
2026S2E2026-09-14100-0.34-0.34-0.34
2026S2E2026-09-08110-0.34-0.34-0.34
2026S2E2026-08-27110-0.34-0.34-0.34
2026S2E2026-07-01110-0.34-0.34-0.34
2026S2E2026-05-26100-0.53-0.53-0.53
2026S2E2026-05-11101-0.53-0.53-0.53
2026S2E2025-11-11100-0.01-0.01-0.01
2026S2E2025-11-10100-0.01-0.01-0.01
2026S2E2025-11-09100-0.01-0.01-0.01
2026S2E2025-11-08100-0.01-0.01-0.01
2026S2E2025-11-07100-0.01-0.01-0.01
2026S2E2025-11-06100-0.01-0.01-0.01

Estimate history

EPS, annual-1178.48-1010.167-884.613-255.52-165.054-74.527-35.728-21.823-12.035
Period201720182019202020212022202320242025
EPS, quarterly-15.95-18.451-22.141-12.839-8.064-8.732
PeriodQ2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23
Sales, annual0.7953.8082.0390.7680.8540.8070.7410.6770.408
Period201720182019202020212022202320242025
Sales, quarterly0.2020.2020.1960.1940.1940.195
PeriodQ2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23
Shares, annual0.0060.0070.020.0770.1360.1360.2270.4971.311
Period201720182019202020212022202320242025
Shares, quarterly0.1360.1360.1360.2040.2040.204
PeriodQ2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.410.410.680.740.810.850.772.043.81
Cost of Goods Sold Incl. D&A0.000.020.010.01-----
Gross Profit0.410.380.670.73-----
Selling, General and Administrative Excl. Other10.2010.418.848.9010.8513.6914.9914.079.19
Research and Development7.166.755.785.977.739.8612.0311.016.05
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.79-10.03-8.17-8.17-10.06-12.85-14.24-12.05-5.40
Interest Expense-0.010.010.010.020.020.390.450.02
Unusual Expense-0.000.01-0.010.23-0.17-0.010.210.00
Net Income Before Taxes-9.61-9.91-7.92-7.61-10.13-12.62-14.54-12.67-6.55
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-9.61-9.91-7.92-7.61-10.13-12.62-14.54-12.67-6.55
Net Income From Continuing Operations-9.61-9.91-7.92-7.61-10.13-12.62-14.54-12.67-6.55
Net Income-9.61-9.91-7.92-7.61-10.13-15.22-15.26-12.67-6.55
EPS (Recurring)-5.18-12.02-21.80-35.77-73.36-166.32-255.66-874.34-1,010.17
EPS (Basic, Before Extraordinaries)-6.30-12.03-21.82-35.73-74.53-165.05-255.52-884.61-1,010.17
EPS (Diluted)-6.30-12.03-21.82-35.73-74.53-165.05-255.52-884.61-1,010.17
EBITDA-9.79-10.00-8.16-8.16-10.04-12.84-14.23-12.03-5.38
Non-Operating Income (Expense)0.180.140.280.560.170.080.070.04-1.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.180.340.360.260.260.400.320.270.19
Price To Sales Ratio13.528.0717.4012.6520.6627.8627.684.646.44
Gross Margin99.5194.0798.9697.98-----
Operating Margin-2,402.92-2,456.79-1,206.23-1,102.96-1,246.42-1,505.51-1,853.08-590.90-141.73
Net Margin-2,358.72-2,426.67-1,169.14-1,027.46-1,255.93-1,782.53-1,986.63-621.31-172.02
Shares Outstanding2.141.310.500.230.140.140.080.020.01
Market Capitalization5.045.042.43------

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Total Revenue0.200.200.20
Cost of Goods Sold Incl. D&A0.000.000.02
Gross Profit0.200.200.18
Selling, General and Administrative Excl. Other4.915.285.12
Research and Development3.483.683.06
Other Operating Expense0.000.000.00
Operating Income-4.71-5.08-4.94
Unusual Expense0.00-0.00
Net Income Before Taxes-4.63-4.98-4.91
Income Taxes0.000.000.00
Consolidated Net Income-4.63-4.98-4.91
Net Income From Continuing Operations-4.63-4.98-4.91
Net Income-4.63-4.98-4.91
EPS (Recurring)-2.50-3.80-8.64
EPS (Basic, Before Extraordinaries)-2.50-3.80-8.65
EPS (Diluted)-2.50-3.80-8.65
EBITDA-4.71-5.08-4.91
Non-Operating Income (Expense)0.080.100.02
Stock Option Compensation Expense0.090.090.25
Price To Sales Ratio13.5212.86-
Gross Margin99.5099.5188.61
Operating Margin-2,316.84-2,488.68-2,424.75
Net Margin-2,277.73-2,439.41-2,413.86
Shares Outstanding2.141.310.66
Market Capitalization5.045.2413.89

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.547.898.927.9919.148.342.763.893.51
Short Term Receivables0.070.080.080.050.050.020.650.040.07
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.831.020.911.120.881.043.733.973.09
Total Current Assets9.448.989.919.1620.079.407.147.906.66
Net Property, Plant & Equipment0.070.140.080.130.190.120.120.050.03
Total Investments and Advances0.000.000.000.000.000.000.000.000.92
Long-Term Note Receivable-----0.000.91--
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.000.01
Total Assets9.519.129.999.2820.259.528.177.957.61
Short Term Debt Incl. Current Port. of LT Debt0.060.050.030.050.050.040.040.000.00
Accounts Payable1.160.620.430.900.950.562.161.070.43
Other Current Liabilities1.511.381.571.561.720.671.082.051.33
Total Current Liabilities2.732.052.022.502.731.273.273.121.75
Long Term Debt0.010.050.010.010.070.020.040.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities1.181.581.712.303.072.162.421.820.85
Total Liabilities3.923.683.754.815.873.455.734.942.60
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.595.446.244.4714.386.072.443.015.01
Total Shareholders Equity5.595.446.244.4714.386.072.443.015.01
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.595.446.244.4714.386.072.443.015.01
Total Liabilities & Stockholders Equity9.519.129.999.2820.259.528.177.957.61
Book Value Per Share4.2710.9327.5532.89105.7878.58121.44447.78903.55
Tangible Book Value Per Share4.2710.9327.5532.89105.7878.58121.44447.78903.55
Full-Time Employees555--8877
Price to Book Ratio0.730.58-------
Return on Assets-106.32-82.87-79.02-68.61-84.79-164.36-157.09-82.94-71.88
Return on Equity-179.65-135.58-142.12-107.49-123.42-418.48-464.21-215.72-143.92
Return on Invested Capital-176.67-144.29-121.71-225.88-87.34-238.51-510.51-217.24-127.41
Quick Ratio3.464.384.903.667.357.412.182.533.80
Current Ratio3.464.384.903.667.357.412.182.533.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-9.60-9.91-7.92-7.61-10.13-12.62-14.54-12.67-6.55
Depreciation0.000.020.010.010.010.010.010.010.01
Other Funds (Non Cash)0.170.430.510.120.660.310.380.621.26
Funds from Operations-9.43-9.46-7.40-7.48-9.46-12.30-14.15-12.03-5.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.130.44-0.27-0.94-1.302.432.010.911.13
Cash from Operating Activities-9.56-9.02-7.67-8.42-10.76-9.86-12.15-11.12-4.14
Capital Expenditures-0.00-0.00-0.01-0.00-0.01-0.01-0.03-0.00-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-4.030.001.510.509.47-14.510.000.000.00
Purchase of Investments-1.010.000.000.000.00-14.510.000.000.00
Sale Or Maturity of Investments-3.020.001.510.509.470.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-4.03-0.001.500.509.46-14.52-0.03-0.00-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.109.726.749.120.0020.4717.8110.204.37
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.109.726.749.120.0020.4717.8110.204.37
Proceedsfrom Stock Options4.182.962.230.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities10.109.726.749.120.0020.4717.8110.204.37
Exchange Rate Effect0.000.01-0.020.10-0.110.03-0.020.00-0.09
Net Change in Cash-3.500.710.551.30-1.41-3.885.61-0.920.11
Free Cash Flow-9.56-9.02-7.68-8.42-10.77-9.88-12.17-11.12-4.17
Preferred Dividends (Cash Flow)-0.000.000.000.00--0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Cash & Short Term Investments7.048.546.46
Short Term Receivables0.000.070.00
Inventories0.000.000.00
Other Current Assets0.960.831.17
Total Current Assets8.009.447.62
Net Property, Plant & Equipment0.050.070.10
Total Investments and Advances0.000.000.00
Intangible Assets0.000.000.00
Other Assets0.000.000.00
Total Assets8.059.517.72
Short Term Debt Incl. Current Port. of LT Debt0.050.060.06
Accounts Payable0.681.161.15
Other Current Liabilities1.501.510.91
Total Current Liabilities2.222.732.12
Long Term Debt0.000.010.03
Other Liabilities0.971.181.38
Total Liabilities3.203.923.54
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity4.855.594.18
Total Shareholders Equity4.855.594.18
Accumulated Minority Interest0.000.000.00
Total Equity4.855.594.18
Total Liabilities & Stockholders Equity8.059.517.72
Book Value Per Share2.274.276.33
Tangible Book Value Per Share2.274.276.33
Price to Book Ratio0.730.943.32
Return on Assets-121.89--
Return on Equity-212.72--
Return on Invested Capital-95.41-88.84-116.54
Quick Ratio3.603.463.60
Current Ratio3.603.463.60

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Net Income-4.63-4.97-4.91
Depreciation0.000.000.02
Other Funds (Non Cash)0.070.100.32
Funds from Operations-4.56-4.87-4.57
Extraordinary Item0.000.000.00
Changes in Working Capital-0.790.66-0.22
Cash from Operating Activities-5.35-4.21-4.79
Capital Expenditures-0.00-0.00-0.00
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments-1.01-3.023.02
Purchase of Investments-1.010.000.00
Sale Or Maturity of Investments0.00-3.023.02
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities-1.01-3.023.02
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock3.806.303.40
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock3.806.303.40
Proceedsfrom Stock Options3.800.382.57
Issuance or Reduction of Debt, Net0.000.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities3.806.303.40
Exchange Rate Effect0.000.000.01
Net Change in Cash-2.56-0.931.64
Free Cash Flow-5.35-4.21-4.79

Revenue breakdown

Pharmaceutical Preparations2024: 674.00K 2025: 405.00K
Israel2024: 674.00K 2025: 405.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-371.21K
2026-10-15-0.0M-361.49K
2026-09-30-0.1M-1.32M
2026-09-15-0.1M-1.75M
2026-08-31-0.1M-1.39M
2026-08-14-0.1M-1.41M
2026-07-31-0.1M-1.44M
2026-07-15-0.1M-1.90M
2026-06-30-0.3M-897.19K
2026-06-15-0.0M-484.11K
2026-05-29-0.1M-1.13M
2026-05-15-0.1M-1.13M
2026-04-30-0.0M-1.13M
2026-04-15-0.0M-706.55K
2026-03-31-0.0M-720.21K
2026-03-13-0.0M-877.60K
2026-02-27-0.1M-217.14K
2026-02-13-0.1M-522.32K
2026-01-30-0.1M-510.68K
2026-01-15-0.1M-493.22K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-09EFFECTEffectiveness filing by commission orderSEC
2026-10-09EFFECTEffectiveness filing by commission orderSEC
2026-10-09424B3SEC
2026-09-25F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-09-25F-3/ASEC
2026-09-11EFFECTEffectiveness filing by commission orderSEC
2026-09-11EFFECTEffectiveness filing by commission orderSEC
2026-09-10DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-08POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-09-08POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-03SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-08-28F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-03SEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-20SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-07-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-06SEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-26SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC1.52%
RHUMBLINE ADVISERS0.64%
GAMMA Investing LLC0.22%
UBS Group AG0.09%
CITIGROUP INC0.07%
BFC Planning, Inc.0.01%
FIFTH THIRD BANCORP0.00%
WELLS FARGO & COMPANY/MN0.00%
Activest Wealth Management0.00%
Avion Wealth0.00%

Funds

Fund% owned
Avantis Emerging Markets Equity ETF21.73%
Avantis Emerging Markets Value ETF3.14%
Avantis Emerging Markets Equity Fund1.33%
Avantis Emerging Markets ex-China Equity ETF0.76%
Avantis Emerging Markets Small Cap Equity ETF0.28%
Avantis Responsible Emerging Markets Equity ETF0.20%
Wilshire International Equity Fund0.12%
Xtrackers Nifty 500 India ETF0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CANF. Cached 15 minutes.

Some panels did not load: insider.